Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 1 55-1, 2004, Pages

  Mac Gabhann, Feilim ^a,b   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Angiogenesis; Kinetics; Mathematical or computational model; Receptor ligand interactions; Synergy

Indexed keywords

GROWTH FACTOR; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BINDING KINETICS; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; COMPLEX FORMATION; ENDOTHELIUM CELL; LIGAND BINDING; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

EID: 0345737075     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00254.2003     Document Type: Article

References (59)

1. Adini A, Kornaga T, Firoozbakht F, and Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 62: 2749-2752, 2002.
2. Athanassiades A and Lala PK. Role of placenta growth factor (P1GF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 19: 465-473, 1998.
3. Barillari G, Albonici L, Franzese O, Modesti A, Liberati F, Barillari P, Ensoli B, Manzari V, and Santeusanio G. The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis. Am J Pathol 152: 1161-1166, 1998.
4. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, and Marme D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 57: 5421-5425, 1997.
5. Berk DA, Yuan F, Leunig M, and Jain RK. Fluorescence photobleaching with spatial Fourier analysis: measurement of diffusion in light-scattering media. Biophys J 65: 2428-2436, 1993.
6. Bikfalvi A, Sauzeau C, Moukadiri H, Maclouf J, Busso N, Bryckaert M, Plouet J, and Tobelem G. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. J Cell Physiol 149: 50-59, 1991.
7. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, and Isner JM. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 97: 469-476, 1996.
8. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, and Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 159: 993-1008, 2001.
9. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, and Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583, 2001.
10. Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, Parolini I, Petrucci E, Pelosi E, Morsilli O, Gabbianelli M, Testa U, and Peschle C. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Fltl receptor. Blood 101: 1316-1323, 2003.
11. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, and Risau W. The vascular endothelial, growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271: 17629-17634, 1996.
12. Cunningham SA, Tran TM, Arrate MP, and Brock TA. Characterization of vascular endothelial cell growth factor interactions with the kinase insert domain-containing receptor tyrosine kinase. A real time kinetic study. J Biol Chem 274: 18421-18427, 1999.
13. Dull RO, Yuan J, Chang YS, Tarbell J, Jain RK, and Munn LL. Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation. Microvasc Res 61: 203-210, 2001.
14. Dunst J, Becker A, Lautenschlager C, Markau S, Becker H, Fischer K, and Haensgen G. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol 178: 436-441, 2002.
15. Fannon M, Forsten KE, and Nugent MA. Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. Biochemistry 39: 1434-1445, 2000.
16. Fannon M and Nugent MA. Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem 271: 17949-17956, 1996.
17. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77: 527-543, 1999.
18. Fong GH, Zhang L, Bryce DM, and Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126: 3015-3025, 1999.
19. Forsten KE, Fannon M, and Nugent MA. Potential mechanisms for the regulation of growth factor binding by heparin. J Theor Biol 205: 215-230, 2000.
20. Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, and Isner JM. Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther 13: 1595-1603, 2002.
21. Haas TL and Duling BR. Morphology favors an endothelial cell pathway for longitudinal conduction within arterioles. Microvasc Res 53: 113-120, 1997.
22. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, and Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 61: 1207-1213, 2001.
23. Hiratsuka S, Minowa O, Kuno J, Noda T, and Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiolgenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354, 1998.
24. Houck KA, Leung DW, Rowland AM, Winer J, and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031-26037, 1992.
25. Huang X, Gottstein C, Brekken RA, and Thorpe PE. Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem Biophys Res Commun 252: 643-648, 1998.
26. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, and Satomi T. Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor. Gastr Cancer 5: 137-141, 2002.
27. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, and Sato Y. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19: 2138-2146, 2000.
28. Lauffenburger DA, Forsten KE, Will B, and Wiley HS. Molecular/cell engineering approach to autocrine ligand control of cell function. Ann Biomed Eng 23: 208-215, 1995.
29. Lauffenburger DA and Linderman JJ. Receptors. New York: Oxford University Press, 1993.
30. Levesque MJ, Liepsch D, Moravec S, and Nerem RM. Correlation of endothelial cell shape and wall shear stress in a stenosed dog aorta. Arteriosclerosis 6: 220-229, 1986.
31. Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, Kapiotis S, Hamwi A, Weich HA, Valent P, Angelberger P, Dudczak R, and Virgolini I. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer 91: 789-796, 2001.
32. Lip PL, Felmeden DC, Blann AD, Matheou N, Thakur S, Cunliffe IA, and Lip GY. Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma. Br J Ophthalmol 86: 1299-1302, 2002.
33. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, and Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 183: 1554-1557, 2000.
34. Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, and Zhu Z. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domaincontaining receptor. Cancer Res 61: 7002-7008, 2001.
35. Luttun A, Brusselmans K, Fukao H, Tjwa M, Ueshima S, Herbert JM, Matsuo O, Cheilion D, Carmeliet P, and Moons L. Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun 295: 428-434, 2002a.
36. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, and Carmeliet P. Revascularization of ischemic tissues by P1GF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831-840, 2002b.
37. Marchand GS, Noiseux N, Tanguay JF, and Sirois MG. Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors. Am J Physiol Heart Circ Physiol 282: H194-H204, 2002.
38. Matsumoto T and Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001: RE21, 2001.
39. Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, and Sato JD. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci USA 88: 5819-5823, 1991.
40. Ng YS, Rohan R, Sunday ME, Demello DE, and D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 220: 112-121, 2001.
41. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, Failla CM, and Zambruno G. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 115: 2559-2567, 2002.
42. Okamoto T, Niu R, Mizutani S, and Yamada S. Levels of placenta growth factor in gestational trophoblastic diseases. Am J Obstet Gynecol 188: 135-140, 2003.
43. Park JE, Chen HH, Winer J, Houck KA, and Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269: 25646-25654, 1994.
44. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, and Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. BrJ Obstet Gynaecol 106: 1019-1022. 1999.
45. Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, and Zioncheck TF. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 273: 29979-29985, 1998.
46. Shvartsman SY, Wiley HS, Deen WM, and Lauffenburger DA. Spatial range of autocrine signaling: modeling and computational analysis. Biophys J 81: 1854-1867, 2001,
47. Sperinde GV and Nugent MA. Heparan sulfate proteoglycans control intracellular processing of bFGF in vascular smooth muscle cells. Biochemistry 37: 13153-13164, 1998.
48. Starbuck C and Lauffenburger DA. Mathematical model for the effects of epidermal growth factor receptor trafficking dynamics on fibroblast proliferation responses. Biotechnol Prog 8: 132-143, 1992.
49. Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB, and Welch WC. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor. FLT-1, inhibit the growth of C6 glioma in a mouse xenograft, J Neurooncol 55: 91-100, 2001.
50. Vega-Diaz B, Herron GS, and Michel S. An autocrine loop mediates expression of vascular endothelial growth factor in human dermal microvascular endothelial cells. J Invest Dermatol 116: 525-530, 2001.
51. Von Tiedemann B and Bilitewski U. Characterization of the vascular endothelial growth factor-receptor interaction and determination of the recombinant protein by an optical receptor sensor. Biosens Bioelectron 17: 983-991, 2002.
52. Vuorela-Vepsalainen P, Alfthan H, Orpana A, Alitalo K, Stenman UH, and Halmesmaki E. Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod 14: 1346-1351, 1999.
53. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, and Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995, 1994.
54. Wang D, Lehman RE, Donner DB, Matli MR, Warren RS, and Welton ML. Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells. Am J Physiol Gastrointest Liver Physiol 282: G1088-G1096, 2002.
55. Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A, and Gerritsen ME. Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 22: 1797-1803, 2002.
56. Zachary I and Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 49: 568-581, 2001.
57. Zeng H, Dvorak HF, and Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276: 26969-26979, 2001.
58. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, and Rosengart TK. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 67: 147-154, 1997.
59. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Paoletti I, Barra A, Tucci M, Parise G, Vincenti V, Granger HJ, Viglietto G, and Persico MG. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 76: 517-531. 1997.